Literature DB >> 27708955

Dermato-neuro syndrome in a case of scleromyxedema.

Yusuf Savran1, Sevgi Akarsu2.   

Abstract

Scleromyxedema is an uncommon connective tissue disease characterized by mucin deposits, fibrosis, and proliferation of fibroblasts in the dermis. Although it shares similar sclerodermoid features, it is a different clinical entity than scleroderma. A monoclonal gammopathy is almost always present; however, progression to multiple myeloma is rare. It may have many systemic manifestations, of which the most notable being the dermato-neuro syndrome because of its rarity and potential fatal outcome. We present a case of a 50-year-old woman with scleromyxedema in whom the dermato-neuro syndrome developed.

Entities:  

Keywords:  Scleromyxedema; connective tissue; dermato-neuro syndrome

Year:  2015        PMID: 27708955      PMCID: PMC5047230          DOI: 10.5152/eurjrheum.2015.0116

Source DB:  PubMed          Journal:  Eur J Rheumatol        ISSN: 2147-9720


  10 in total

1.  The neurologic complications of scleromyxedema.

Authors:  J R Berger; M R Dobbs; M H Terhune; W F Maragos
Journal:  Medicine (Baltimore)       Date:  2001-09       Impact factor: 1.889

2.  Coma associated with scleromyxoedema and interferon alfa therapy. Full recovery after steroids and cyclophosphamide combined with plasmapheresis.

Authors:  F Rongioletti; A Hazini; A Rebora
Journal:  Br J Dermatol       Date:  2001-06       Impact factor: 9.302

3.  Lichen myxedematosus with systemic involvement: clinical and autopsy findings.

Authors:  B Loggini; R Pingitore; A Avvenente; G Giuliano; P Barachini
Journal:  J Am Acad Dermatol       Date:  2001-10       Impact factor: 11.527

Review 4.  Scleromyxedema revisited.

Authors:  John J Pomann; Earl J Rudner
Journal:  Int J Dermatol       Date:  2003-01       Impact factor: 2.736

5.  Scleromyxedema and dermato–neuro syndrome in a patient with multiple myeloma effectively treated with dexamethasone and bortezomib.

Authors:  Nicole M Fett; Mary B Toporcer; Josep Dalmau; Michi M Shinohara; Dan T Vogl
Journal:  Am J Hematol       Date:  2011-10       Impact factor: 10.047

6.  Scleromyxedema: a case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG).

Authors:  Marissa Blum; Fredrick M Wigley; Laura K Hummers
Journal:  Medicine (Baltimore)       Date:  2008-01       Impact factor: 1.889

7.  Arndt-Gottron scleromyxoedema: successful therapy with intravenous immunoglobulins.

Authors:  P Gholam; M Hartmann; A Enk
Journal:  Br J Dermatol       Date:  2007-09-13       Impact factor: 9.302

Review 8.  Scleromyxedema and the dermato-neuro syndrome: case report and review of the literature.

Authors:  Kirsten E Fleming; Divya Virmani; Evelyn Sutton; Richard Langley; Jessica Corbin; Sylvia Pasternak; Noreen M Walsh
Journal:  J Cutan Pathol       Date:  2012-05       Impact factor: 1.587

Review 9.  Scleromyxedema.

Authors:  Laura K Hummers
Journal:  Curr Opin Rheumatol       Date:  2014-11       Impact factor: 5.006

10.  Treatment of scleromyxedema and the dermatoneuro syndrome with intravenous immunoglobulin.

Authors:  Jeanmarie B Rey; Rebecca B Luria
Journal:  J Am Acad Dermatol       Date:  2009-02-26       Impact factor: 11.527

  10 in total
  1 in total

1.  Scleromyxedema in a 21 year old female patient with acute lymphoblastic leukemia: a case report.

Authors:  Hadi Rabee; Leeda Tayem; Mohammad Gharbeyah; Dina Abugaber
Journal:  BMC Dermatol       Date:  2020-12-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.